3 documents found, page 1 of 1
Trimetazidine in cardiovascular medicine
Marzilli, Mario; Vinereanu, Dragos; Lopaschuk, Gary; Chen, Yundai; Dalal, Jamshed J; Danchin, Nicolas; Etriby, El; Ferrari, RobertoAbnormalities of myocardial energy metabolism appear as a common background of the two major cardiac disorders: ischemic heart disease (IHD) and heart failure (HF). Myocardial ischemia has been recently conceived as a multifaceted syndrome that can be precipitated by a number of mechanisms including metabolic abnormalities. HF is a progressive disorder characterised by a complex interaction of haemodynamic, neu...
Anti-anginal drugs : systematic review and clinical implications
Pavasini, Rita; Camici, Paolo G; Crea, Filippo; Danchin, Nicolas; Fox, Kim; Manolis, Athanasios J; Marzilli, Mario; Rosano, Giuseppe M CBackground:The cornerstone of the treatment of patients affected by stable angina is based on drugs administration classified as first (beta-blockers, calcium channel blockers, short acting nitrates) or second line treatment (long-acting nitrates, ivabradine, nicorandil, ranolazine and trimetazidine). However, few data on comparison between different classes of drugs justify that one class of drugs is superior ...
Anti-anginal drugs–beliefs and evidence : systematic review covering 50 years o...
Ferrari, Roberto; Pavasini, Rita; Camici, Paolo G.; Crea, Filippo; Danchin, Nicolas; Pinto, Fausto J.; Manolis, Athanasios; Marzilli, MarioChronic stable angina is the most prevalent symptom of ischaemic heart disease and its management is a priority. Current guidelines recommend pharmacological therapy with drugs classified as being first line (beta blockers, calcium channel blockers, short acting nitrates) or second line (long-acting nitrates, ivabradine, nicorandil, ranolazine, and trimetazidine). Second line drugs are indicated for patients wh...